RCEL - AVITA Medical, Inc.
IEX Last Trade
13.6
0.030 0.221%
Share volume: 3,279
Last Updated: Fri 27 Dec 2024 08:30:30 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$13.57
0.03
0.22%
Fundamental analysis
25%
Profitability
25%
Dept financing
9%
Liquidity
75%
Performance
17%
Performance
5 Days
12.09%
1 Month
2.49%
3 Months
22.63%
6 Months
65.66%
1 Year
-9.61%
2 Year
98.34%
Key data
Stock price
$13.60
DAY RANGE
$13.06 - $13.78
52 WEEK RANGE
$7.95 - $18.93
52 WEEK CHANGE
-$4.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: James M. Corbett
Region: US
Website: avitamedical.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: avitamedical.com
Employees: 130
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company was incorporated in 2000 and is based in Valencia, California.
Recent news